Please login to the form below
vildagliptin
This page shows the latest vildagliptin news and features for those working in and with pharma, biotech and healthcare.
Novartis to make 15 drugs available at $1 a month
Among the drugs to be made available under the scheme are high blood pressure medicine valsartan, tamoxifen for breast cancer and vildagliptin for diabetes.
Latest news
-
AZ sues to block generic saxagliptin from Mylan
world market for DPP4 inhibitors, a class which also includes Merck &Co's market-leading Januvia (sitagliptin), Novartis' Galvus (vildagliptin) and Boehringer Ingelheim/Lilly's Trajenta (linagliptin).
-
Pfizer still number one - just
Meanwhile, Novartis kept the pressure on with solid performances for its own new entrants, including Gilenya (fingolimod) for multiple sclerosis, cancer drugs Afinitor/Votubia (everolimus) and Tasigna (nilotinib) and Galvus (vildagliptin)
-
NICE turns down Afinitor for breast cancer
for leukaemia, Galvus (vildagliptin) for diabetes and blood cancer therapy Jakavi (ruxolitinib).
-
Novartis lifts 2013 guidance on delay to Diovan generics
Gilenya (fingolimod), Afinitor (everolimus) for breast cancer, leukaemia therapy Tasigna (nilotinib) and Galvus (vildagliptin) for diabetes just about offsetting revenue losses to generic competition of some $800m in the quarter.
-
Setback for AZ and BMS as Onglyza flunks cardiovascular trial
vildagliptin). The trial was set up in the wake of new US FDA guidelines in 2009 which required pharma companies to perform cardiovascular outcome studies on new diabetes drugs.
AZ sues to block generic saxagliptin from Mylan
Pfizer still number one - just
NICE turns down Afinitor for breast cancer
Novartis lifts 2013 guidance on delay to Diovan generics
Setback for AZ and BMS as Onglyza flunks cardiovascular trial
More from news
Approximately 0 fully matching, plus 25 partially matching documents found.
Latest appointments
-
bmore creative hires Kush Rach as new business director
He was a key account manager at the pharma company, where he worked in the diabetes therapeutic area, and was involved in the UK launch of Galvus (vildagliptin) for type 2
bmore creative hires Kush Rach as new business director
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
CEO, Head of Health, UK
-
Six figure salary
-
Omnichannel Strategy Consultant
-
Competitive Salary
-
Senior Account Manager
-
Competitive salary offered
-
CEO Pricing & Market Access, UK
-
Six figure salary
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Biosimilars boosted by FDA's landmark ruling for Boehringer’s Cyltezo
- US demand for COVID-19 antibody treatments rising fast
- Valneva COVID-19 vaccine more effective than AZ
- EU “still interested” in Valneva COVID vaccine despite UK snub
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Call for industry innovators to join working group
- Pfizer-BioNTech booster offers 95.6% efficacy against COVID-19
- US COVID-19 booster programme expanded
- The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
- Mind the Gap – Challenging Immunisation Apathy and Misinformation
- Towards Better HCP Engagement – An Email Masterclass
- Engaging HCPs on their own terms: how pharma can adapt to the post-pandemic digital era
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Beyond yoga and smoothies – providing real support for employee well-being
- The Future of eHealth: Contactless Health Monitoring
- Reckitt to spin-off pharma unit as Indivior
- Results of AstraZeneca’s TACKLE phase 3 trial show antibody combination reduces risk of severe COVID-19 or death
Latest intelligence
- The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
- The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
- Mind the Gap – Challenging Immunisation Apathy and Misinformation
- world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
- Towards Better HCP Engagement – An Email Masterclass
- 6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....
